TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation
Journal of Clinical Investigation · 01.05.2024 · 134 (9)
DOI: 10.1172/jci165689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 14.03.2024. Verfasst von Hong Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Intramural Research, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, North Carolina, USA. Hauptthemen laut MEDLINE: Cell Differentiation, Th2 Cells, Thromboxane A2, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
In lung, thromboxane A 2 (TXA 2 ) activates the TP receptor to induce proinflammatory and bronchoconstrictor effects. Thus, TP receptor antagonists and TXA 2 synthase inhibitors have been tested as potential asthma therapeutics in humans. Th9 cells play key roles in asthma and regulate the lung immune response to allergens. Herein, we found that TXA 2 reduces Th9 cell differentiation during allergic lung inflammation. Th9 cells were decreased approximately 2-fold and airway hyperresponsiveness was attenuated in lungs of allergic mice treated with TXA 2 . Naive CD4 + T cell differentiation to Th9 cells and IL-9 production were inhibited dose-dependently by TXA 2 in vitro. TP receptor–deficient mice had an approximately 2-fold increase in numbers of Th9 cells in lungs in vivo after OVA exposure compared with wild-type mice. Naive CD4 + T cells from TP-deficient mice exhibited increased Th9 cell differentiation and IL-9 production in vitro compared with CD4 + T cells from wild-type mice. TXA 2 also suppressed Th2 and enhanced Treg differentiation both in vitro and in vivo. Thus, in contrast to its acute, proinflammatory effects, TXA 2 also has longer-lasting immunosuppressive effects that attenuate the Th9 differentiation that drives asthma progression. These findings may explain the paradoxical failure of anti-thromboxane therapies in the treatment of asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Intramural Research, National Institute of Environmental Health Sciences/NIH, Research Triangle Park, North Carolina, USA.
- Department of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
- Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore.
Förderung
- Intramural NIH HHS
- National Institutes of Health
Zitieren
APA
Li, H., Bradbury, J. A., Edin, M. L., Gruzdev, A., Li, H., Graves, J. P., DeGraff, L. M., Lih, F. B., Feng, C., Wolf, E. R., Bortner, C. D., London, S. J., Sparks, M. A., Coffman, T. M., & Zeldin, D. C. (2024). TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation. Journal of Clinical Investigation, 134(9). https://doi.org/10.1172/jci165689
Vancouver
Li H, Bradbury JA, Edin ML, Gruzdev A, Li H, Graves JP, et al. TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation. Journal of Clinical Investigation. 2024;134(9). doi:10.1172/jci165689
BibTeX
@article{Li2024,
author = {Li, Hong and Bradbury, J Alyce and Edin, Matthew L and Gruzdev, Artiom and Li, Huiling and Graves, Joan P and DeGraff, Laura M and Lih, Fred B and Feng, Chiguang and Wolf, Erin R and Bortner, Carl D and London, Stephanie J and Sparks, Matthew A and Coffman, Thomas M and Zeldin, Darryl C},
title = {TXA2 attenuates allergic lung inflammation through regulation of Th2, Th9, and Treg differentiation},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {9},
doi = {10.1172/jci165689}
}
EUVIMED